SecBot SecBot
Insider Buy ·Filed Jul 20, 2026

ARTV

Artiva Biotherapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001231919-26-000774
Insider cluster: 1 insiders, $1.6M total
Actionable Insight ▲ Bullish

RA Capital's $1.56M open-market purchase is a strong bullish signal from a sophisticated healthcare investor.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$10.00
T+0 close · Jul 20, 2026 · via day close
Latest settled
−40.90%
T+60 · $5.91
Vs SPY
−43.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 21 $10.00entry
  2. T+1 · 4mo ago +0.20%α +0.32% · $10.02
  3. T+5 · 4mo ago +3.20%α +4.43% · $10.32
  4. T+20 · 3mo ago +16.80%α +14.24% · $11.68
  5. T+60 · 5w ago −40.90%α −43.75% · $5.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

RA Capital Management, a 10% owner and director, purchased $1.56M in ARTV stock over a week, including a $1.36M block on July 16. This is a significant insider conviction buy at ~0.65% of market cap, signaling strong confidence from a sophisticated healthcare investor ahead of potential catalysts.

Key Financial Metrics

Direction
buying
Total Value
$1.6M
Insiders
1

Key Facts

  • RA Capital Management (10% owner/director) purchased $1.56M in ARTV stock from July 10-16
  • Largest single trade: 152,472 shares at $8.93 for $1.36M on July 16
  • Total insider buying over 30 days: $1.9M across 6 transactions
  • Market cap: $241M; purchase represents ~0.65% of market cap
  • 92% analyst consensus bullish (11 of 12 analysts rate Buy or Strong Buy)

Financial Impact

Insider purchase of $1.56M represents 0.65% of market cap, a significant signal from a 10% owner

insider ownershipmarket confidence

Risk Factors

  • Biotech sector risk: clinical-stage company with no approved products
  • Insider buying concentrated in one 10% owner; not a broad C-suite cluster

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001231919-26-000774

Track record

33 reports on ARTV

Performance horizon

10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 5h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026